The peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations in bronchoscopic cytological specimens of non-small cell lung cancer

Oncology (Switzerland)

Volumn 82, Issue 6, 2012, Pages 341-346

  Yamada, Noriyuki ^a   Oizumi, Satoshi ^a   Asahina, Hajime ^a   Shinagawa, Naofumi ^a   Kikuchi, Eiki ^a   Kikuchi, Junko ^a   Sakakibara Konishi, Jun ^a   Tanaka, Tomoaki ^b   Kobayashi, Kunihiko ^c   Hagiwara, Koichi ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Bronchoscopy; Cytological specimens; Epidermal growth factor receptor mutations; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PEPTIDE NUCLEIC ACID;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BRONCHOSCOPE; BRONCHOSCOPY; CANCER PATIENT; CANCER TISSUE; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PEPTIDE NUCLEIC ACID LOCKED NUCLEIC ACID POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSBRONCHIAL ASPIRATION;

ADULT; AGED; AGED, 80 AND OVER; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84861892217     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000338327     Document Type: Article

References (28)

1. Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110. (Pubitemid 36331969)
2. Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potentialfor cancer therapy. Cancer Res 2002; 62: 5749-5754. (Pubitemid 35204731)
3. Pérez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with nonsmall- cell lung cancer. J Clin Oncol 2004; 22: 3238-3247. (Pubitemid 41103678)
4. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness ofnon-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
5. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500. (Pubitemid 38720929)
6. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311. (Pubitemid 39209661)
7. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy- naive patients with advancednon-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340-3346. (Pubitemid 46638887)
8. Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006; 95: 998-1004. (Pubitemid 44606825)
9. Sutani A, Nagai Y, Udagawa K, et al: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acidlocked nucleic acid PCR clamp. Br J Cancer 2006; 95: 1483-1489. (Pubitemid 44863350)
10. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
11. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
12. Yasufuku K, Chiyo M, Sekine Y, et al: Realtime endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest 2004; 126: 122-128. (Pubitemid 38943127)
13. Yasufuku K, Chiyo M, Koh E, et al: Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer 2005; 50: 347-354.
14. Kurimoto N, Miyazawa T, Okimasa S, et al: Endobronchial ultrasonography using a guide sheath increases the ability to diagnose peripheral pulmonary lesions endoscopically. Chest 2004; 126: 959-965. (Pubitemid 39258054)
15. Yamada N, Yamazaki K, Kurimoto N, et al: Factors related to diagnostic yield of transbronchial biopsy using endobronchial ultrasonography with a guide sheath in small peripheral pulmonary lesions. Chest 2007; 132: 603-608. (Pubitemid 47282395)
16. Asano F, Matsuno Y, Matsushita T, et al: Transbronchial diagnosis of a small peripheral pulmonary lesion using an ultrathin bronchoscope with virtual bronchoscopic navigation. J Bronchol 2002; 9: 108-111. (Pubitemid 34411955)
17. Shinagawa N, Yamazaki K, Onodera Y, et al: CT-guided transbronchial biopsy using an ultrathin bronchoscope with virtual bronchoscopic navigation. Chest 2004; 125: 1138-1143. (Pubitemid 38367311)
18. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005; 65: 7276-7282. (Pubitemid 41161259)
19. Tanaka T, Nagai Y, Miyazawa H, et al: Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clampbased test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007; 98: 246-252. (Pubitemid 44941878)
20. Tanaka T, Matsuoka M, Sutani A, et al: Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010; 126: 651-655.
21. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC: Pathology and genetics of tumours of the lung, pleura, thymus and heart; in: World Health Organization Classificationof Tumours. IARC Press, Lyon, 2004.
22. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ: American Joint Committee on Cancer. Lung. AJCC Manual for Staging of Cancer. Philadelphia, Lippincott, 1992, pp 115- 122.
23. Yoshida K, Yatabe Y, Park JY, et al: Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2007; 2: 22-28. (Pubitemid 47163924)
24. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346. (Pubitemid 40425952)
25. Nomoto K, Tsuta K, Takano T, et al: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006; 126: 608-615. (Pubitemid 44498512)
26. Oshita F, Matsukuma S, Yoshihara M, et al:Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer 2006; 95: 1070-1075. (Pubitemid 44606834)
27. Horiike A, Kimura H, Nishio K, et al: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007; 131: 1628-1634. (Pubitemid 46981613)
28. Hirsch FR, Bunn PA Jr: EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009; 10: 432-433.